Pomerantz Law Firm Issues Investor Alert About Aldeyra Therapeutics Class Action Lawsuit and Deadlines

Investor Alert: Class Action Lawsuit Against Aldeyra Therapeutics, Inc.

Pomerantz LLP has announced a reminder for investors regarding the class action lawsuit filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). This lawsuit arises from allegations of securities fraud and unlawful business practices linked to the company and its executives. The firm is urging affected investors to take immediate action due to approaching deadlines.

Background of the Lawsuit

The class action covers investors who purchased Aldeyra securities during a specific class period. They have until May 29, 2026, to request the Court to appoint them as Lead Plaintiff. Interested investors are encouraged to contact Danielle Peyton at Pomerantz to discuss their situation, including the number of shares they bought and their contact information. The firm emphasizes that those who reach out via email should include their mailing address and phone number to facilitate further communication.

Allegations of Securities Fraud

The class action claims that Aldeyra, along with its officers and directors, may have engaged in fraudulent behavior that misled investors. The lawsuit's basis stems from a press release issued by Aldeyra on March 17, 2026, where the company disclosed receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for reproxalap, a drug intended for the treatment of dry eye disease.

According to Aldeyra, the CRL noted significant deficiencies in the data presented, concluding that there was inadequate evidence to demonstrate the drug's effectiveness. This communication raised severe doubts about the reliability of previous clinical studies, suggesting that Aldeyra failed to meet the FDA's standards for approval.

In conjunction with the press release, Aldeyra's stock price took a dramatic hit, plummeting nearly 71% to close at $1.24 per share on the day of the announcement. This financial impact is a primary concern for the investors now involved in the class action lawsuit.

Pomerantz LLP: A Leader in Class Action Litigation

Pomerantz LLP is regarded as one of the top firms when it comes to corporate, securities, and antitrust class action litigation. Founded over 85 years ago by Abraham L. Pomerantz, known as a pioneer in the field, the firm's ongoing commitment to protecting the rights of investors is evident through their substantial recoveries for class members in similar cases.

By offering experienced legal guidance, Pomerantz ensures that victims of securities fraud, fiduciary breaches, and corporate misconduct have the opportunity to seek justice. Moreover, their broad geographical presence, with offices located in cities such as New York, Chicago, Los Angeles, and even internationally in London and Tel Aviv, adds to their credibility and ability to assist investors across various regions.

Taking Action

For those who feel they have suffered losses due to their investment in Aldeyra, now is the time to act. Pomerantz encourages individuals to gather all relevant documentation regarding their shares and reach out to their office promptly. Additionally, for those seeking further information about joining the class action, a copy of the legal complaint is available on the firm’s website, providing transparency and clarity regarding the legal proceedings.

In conclusion, the ongoing developments regarding Aldeyra Therapeutics serve as a critical reminder of the inherent risks associated with investment in biotech firms, especially as they navigate the complex regulatory landscape. Investors are urged to stay informed and proactive in protecting their interests as this situation evolves.